Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2016

Open Access 01-12-2016 | Review

Imaging metabolic heterogeneity in cancer

Authors: Debanti Sengupta, Guillem Pratx

Published in: Molecular Cancer | Issue 1/2016

Login to get access

Abstract

As our knowledge of cancer metabolism has increased, it has become apparent that cancer metabolic processes are extremely heterogeneous. The reasons behind this heterogeneity include genetic diversity, the existence of multiple and redundant metabolic pathways, altered microenvironmental conditions, and so on. As a result, methods in the clinic and beyond have been developed in order to image and study tumor metabolism in the in vivo and in vitro regimes. Both regimes provide unique advantages and challenges, and may be used to provide a picture of tumor metabolic heterogeneity that is spatially and temporally comprehensive. Taken together, these methods may hold the key to appropriate cancer diagnoses and treatments in the future.
Literature
1.
2.
3.
Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011;11:85–95.PubMedCrossRef
4.
Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4:891–9.PubMedCrossRef
5.
Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med. 2008;49:24S–42S.PubMedCrossRef
6.
Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029–33.PubMedPubMedCentralCrossRef
7.
Altenberg B, Greulich K. Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics. 2004;84:1014–20.PubMedCrossRef
8.
Viale A, Pettazzoni P, Lyssiotis CA, Ying H, Sánchez N, Marchesini M, et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature. 2014;514:628–32.PubMedPubMedCentralCrossRef
9.
Migneco G, Whitaker-Menezes D, Chiavarina B, Castello-Cros R, Pavlides S, Pestell RG, et al. Glycolytic cancer associated fibroblasts promote breast cancer tumor growth, without a measurable increase in angiogenesis: evidence for stromal-epithelial metabolic coupling. Cell Cycle. 2010;9:2412–22.PubMedCrossRef
10.
Martinez-Outschoorn UE, Whitaker-Menezes D, Valsecchi M, Martinez-Cantarin MP, Dulau-Florea A, Gong J, et al. Reverse warburg effect in a patient with aggressive B-cell lymphoma: is lactic acidosis a paraneoplastic syndrome?. Seminars Oncol. 2013;40(4):403–18. WB Saunders.
11.
Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 2004;64:3892–9.PubMedCrossRef
12.
13.
Gordan JD, Thompson CB, Simon MC. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell. 2007;12:108–13.PubMedPubMedCentralCrossRef
14.
Shakya A, Cooksey R, Cox JE, Wang V, McClain DA, Tantin D. Oct1 loss of function induces a coordinate metabolic shift that opposes tumorigenicity. Nat Cell Biol. 2009;11:320–7.PubMedCrossRef
15.
16.
Schulze A, Harris AL. How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature. 2012;491:364–73.PubMedCrossRef
17.
Vander Heiden MG. Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov. 2011;10:671–84.PubMedCrossRef
18.
Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883–92.PubMedCrossRef
19.
20.
Bonavia R, Mukasa A, Narita Y, Sah DW, Vandenberg S, Brennan C, et al. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev. 2010;24:1731–45.PubMedPubMedCentralCrossRef
21.
Pereira SL, Rodrigues AS, Sousa MI, Correia M, Perestrelo T, Ramalho-Santos J. From gametogenesis and stem cells to cancer: common metabolic themes. Hum Reprod Update. 2014:924-943.
22.
Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–11.PubMedCrossRef
23.
Simsek T, Kocabas F, Zheng J, DeBerardinis RJ, Mahmoud AI, Olson EN, et al. The distinct metabolic profile of hematopoietic stem cells reflects their location in a hypoxic niche. Cell Stem Cell. 2010;7:380–90.PubMedPubMedCentralCrossRef
24.
Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. BBA-Rev Cancer. 1805;2010:105–17.
25.
Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S, et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol. 2007;25:1315–21.PubMedCrossRef
26.
Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol. 2004;5:738–43.PubMedCrossRef
27.
Hill RP. Identifying cancer stem cells in solid tumors: case not proven. Cancer Res. 2006;66:1891–6.PubMedCrossRef
28.
Rossignol R, Gilkerson R, Aggeler R, Yamagata K, Remington SJ, Capaldi RA. Energy substrate modulates mitochondrial structure and oxidative capacity in cancer cells. Cancer Res. 2004;64:985–93.PubMedCrossRef
29.
Smolková K, Bellance N, Scandurra F, Génot E, Gnaiger E, Plecitá-Hlavatá L, et al. Mitochondrial bioenergetic adaptations of breast cancer cells to aglycemia and hypoxia. J Bioenerg Biomembr. 2010;42:55–67.PubMedCrossRef
30.
Jose C, Bellance N, Rossignol R. Choosing between glycolysis and oxidative phosphorylation: a tumor’s dilemma? BBA-Bioenergetics. 1807;2011:552–61.
31.
Guillaumond F, Leca J, Olivares O, Lavaut M-N, Vidal N, Berthezène P, et al. Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma. Proc Natl Acad Sci U S A. 2013;110:3919–24.PubMedPubMedCentralCrossRef
32.
Howlett AR, Petersen OW, Bissell MJ, Steeg PS. A novel function for the nm23-H1 gene: overexpression in human breast carcinoma cells leads to the formation of basement membrane and growth arrest. J Natl Cancer Inst. 1994;86:1838–44.PubMedPubMedCentralCrossRef
33.
Bissell MJ, Hines WC. Why don’t we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med. 2011;17:320–9.PubMedPubMedCentralCrossRef
34.
Guppy M. The hypoxic core: a possible answer to the cancer paradox. Biochem Biophys Res Commun. 2002;299:676–80.PubMedCrossRef
35.
Zu XL, Guppy M. Cancer metabolism: facts, fantasy, and fiction. Biochem Biophys Res Commun. 2004;313:459–65.PubMedCrossRef
36.
Thupari JN, Pinn ML, Kuhajda FP. Fatty acid synthase inhibition in human breast cancer cells leads to malonyl-CoA-induced inhibition of fatty acid oxidation and cytotoxicity. Biochem Biophys Res Commun. 2001;285:217–23.PubMedCrossRef
37.
Fan J, Kamphorst JJ, Mathew R, Chung MK, White E, Shlomi T, et al. Glutamine‐driven oxidative phosphorylation is a major ATP source in transformed mammalian cells in both normoxia and hypoxia. Mol Syst Biol. 2013;9:712.PubMedPubMedCentralCrossRef
38.
Guppy M, Leedman P, Zu X, Russell V. Contribution by different fuels and metabolic pathways to the total ATP turnover of proliferating MCF-7 breast cancer cells. Biochem J. 2002;364:309–15.PubMedPubMedCentralCrossRef
39.
Huang B, Law MW-M, Khong P-L. Whole-body PET/CT scanning: estimation of radiation dose and cancer risk. Radiology. 2009;251:166–74.PubMedCrossRef
40.
Elhami E, Goertzen AL, Xiang B, Deng J, Stillwell C, Mzengeza S, et al. Viability and proliferation potential of adipose-derived stem cells following labeling with a positron-emitting radiotracer. Eur J Nucl Med Mol Imaging. 2011;38:1323–34.PubMedCrossRef
41.
May MS, Brand M, Wuest W, Anders K, Kuwert T, Prante O, et al. Induction and repair of DNA double-strand breaks in blood lymphocytes of patients undergoing 18F-FDG PET/CT examinations. Eur J Nucl Med Mol Imaging. 2012;39:1712–9.PubMedCrossRef
42.
Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol. 2005;202:654–62.PubMedCrossRef
43.
Bell GI, Kayano T, Buse JB, Burant CF, Takeda J, Lin D, et al. Molecular biology of mammalian glucose transporters. Diabetes Care. 1990;13:198–208.PubMedCrossRef
44.
Bar-Shalom R, Yefremov N, Guralnik L, Gaitini D, Frenkel A, Kuten A, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med. 2003;44:1200–9.PubMed
45.
Phelps M, Huang S, Hoffman E, Selin C, Sokoloff L, Kuhl D. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F‐18) 2‐fluoro‐2‐deoxy‐D‐glucose: validation of method. Ann Neurol. 1979;6:371–88.PubMedCrossRef
46.
Di Chiro G. Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors: a powerful diagnostic and prognostic tool. Invest Radiol. 1987;22:360–71.PubMedCrossRef
47.
Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer. 2002;2:683–93.PubMedCrossRef
48.
Wahl RL, Zasadny K, Helvie M, Hutchins G, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol. 1993;11:2101–11.PubMed
49.
Findlay M, Young H, Cunningham D, Iveson A, Cronin B, Hickish T, et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol. 1996;14:700–8.PubMed
50.
Wieder HA, Brücher BL, Zimmermann F, Becker K, Lordick F, Beer A, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol. 2004;22:900–8.PubMedCrossRef
51.
Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics. 1999;19:61–77.PubMedCrossRef
52.
Bos R, van der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, Comans EF, et al. Biologic correlates of 18fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;20:379–87.PubMedCrossRef
53.
Zhuang H, Cortes-Blanco A, Pourdehnad M, Adam L-E, Yamamoto A, Martinez-Lazaro R, et al. Do high glucose levels have differential effect on FDG uptake in inflammatory and malignant disorders? Nucl Med Commun. 2001;22:1123–8.PubMedCrossRef
54.
Schirrmeister H, Kühn T, Guhlmann A, Santjohanser C, Hörster T, Nüssle K, et al. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med. 2001;28:351–8.PubMedCrossRef
55.
Moses WW. Fundamental limits of spatial resolution in PET. Nucl Instrum Methods Phys Res A. 2011;648:S236–40.PubMedCrossRef
56.
Cheng KW, Agarwal R, Mitra S, Lee JS, Carey M, Gray JW, et al. Rab25 increases cellular ATP and glycogen stores protecting cancer cells from bioenergetic stress. EMBO Mol Med. 2012;4:125–41.PubMedPubMedCentralCrossRef
57.
Lieberman BP, Ploessl K, Wang L, Qu W, Zha Z, Wise DR, et al. PET imaging of glutaminolysis in tumors by 18F-(2S, 4R) 4-fluoroglutamine. J Nucl Med. 2011;52:1947–55.PubMedCrossRef
58.
Oyama N, Akino H, Kanamaru H, Suzuki Y, Muramoto S, Yonekura Y, et al. 11C-acetate PET imaging of prostate cancer. J Nucl Med. 2002;43:181–6.PubMed
59.
Scher B, Seitz M, Albinger W, Tiling R, Scherr M, Becker H-C, et al. Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging. 2007;34:45–53.PubMedCrossRef
60.
Picchio M, Spinapolice EG, Fallanca F, Crivellaro C, Giovacchini G, Gianolli L. Messa C: [11C] Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy. Eur J Nucl Med Mol Imaging. 2012;39:13–26.PubMedCrossRef
61.
Baek S, Choi C-M, Ahn SH, Lee JW, Gong G, Ryu J-S, et al. Exploratory clinical trial of (4S)-4-(3-[18F] fluoropropyl)-l-glutamate for imaging xC− transporter using positron emission tomography in patients with non–small cell lung or breast cancer. Clin Cancer Res. 2012;18:5427–37.PubMedCrossRef
62.
Ho C-L, Simon C, Yeung DW. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med. 2003;44:213–21.PubMed
63.
64.
Witney TH, Pisaneschi F, Alam IS, Trousil S, Kaliszczak M, Twyman F, et al. Preclinical evaluation of 3-18F-fluoro-2, 2-dimethylpropionic acid as an imaging agent for tumor detection. J Nucl Med. 2014;55:1506–12.PubMedCrossRef
65.
Shields AF, Grierson JR, Dohmen BM, Machulla H-J, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [F-18] FLT and positron emission tomography. Nat Med. 1998;4:1334–6.PubMedCrossRef
66.
Krohn KA, Mankoff DA, Eary JF. Imaging cellular proliferation as a measure of response to therapy. J Clin Pharmacol. 2001;41:96S–103S.CrossRef
67.
Yagle KJ, Eary JF, Tait JF, Grierson JR, Link JM, Lewellen B, et al. Evaluation of 18 F-annexin V as a PET imaging agent in an animal model of apoptosis. J Nucl Med. 2005;46:658–66.PubMed
68.
van Kruchten M, Glaudemans AW, de Vries EF, Beets-Tan RG, Schröder CP, Dierckx RA, et al. PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma. J Nucl Med. 2012;53:182–90.PubMedCrossRef
69.
Dijkers E, Oude Munnink T, Kosterink J, Brouwers A, Jager P, Jong J, et al. Biodistribution of 89Zr‐trastuzumab and PET imaging of HER2‐positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87:586–92.PubMedCrossRef
70.
Eschmann S-M, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G, et al. Prognostic impact of hypoxia imaging with 18 F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med. 2005;46:253–60.PubMed
71.
Glaudemans AW, Enting RH, Heesters MA, Dierckx RA, van Rheenen RW, Walenkamp AM, et al. Value of 11C-methionine PET in imaging brain tumours and metastases. Eur J Nucl Med Mol Imaging. 2013;40:615–35.PubMedCrossRef
72.
Chung J-K, Kim Y, Kim S-k, Lee Y, Paek S, Yeo J, et al. Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo-or isometabolic on 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2002;29:176–82.PubMedCrossRef
73.
Pöpperl G, Kreth FW, Mehrkens JH, Herms J, Seelos K, Koch W, et al. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging. 2007;34:1933–42.PubMedCrossRef
74.
Gillies RJ, Morse DL. In vivo magnetic resonance spectroscopy in cancer. Annu Rev Biomed Eng. 2005;7:287–326.PubMedCrossRef
75.
Jagannathan N, Kumar M, Seenu V, Coshic O, Dwivedi S, Julka P, et al. Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br J Cancer. 2001;84:1016.PubMedPubMedCentralCrossRef
76.
Muruganandham M, Alfieri AA, Matei C, Chen Y, Sukenick G, Schemainda I, et al. Metabolic signatures associated with a NAD synthesis inhibitor–induced tumor apoptosis identified by 1H-decoupled-31P magnetic resonance spectroscopy. Clin Cancer Res. 2005;11:3503–13.PubMedCrossRef
77.
Nielsen FU, Daugaard P, Bentzen L, Stødkilde-Jørgensen H, Overgaard J, Horsman MR, et al. Effect of changing tumor oxygenation on glycolytic metabolism in a murine C3H mammary carcinoma assessed by in vivo nuclear magnetic resonance spectroscopy. Cancer Res. 2001;61:5318–25.PubMed
78.
Chan KW, McMahon MT, Kato Y, Liu G, Bulte JW, Bhujwalla ZM, et al. Natural D‐glucose as a biodegradable MRI contrast agent for detecting cancer. Magn Reson Med. 2012;68:1764–73.PubMedPubMedCentralCrossRef
79.
Walker-Samuel S, Ramasawmy R, Torrealdea F, Rega M, Rajkumar V, Johnson SP, et al. In vivo imaging of glucose uptake and metabolism in tumors. Nat Med. 2013;19:1067–72.PubMedCrossRef
80.
Cai K, Xu HN, Singh A, Moon L, Haris M, Reddy R, et al. Breast cancer redox heterogeneity detectable with chemical exchange saturation transfer (CEST) MRI. Mol Imaging Biol. 2014;16:670–9.PubMedPubMedCentralCrossRef
81.
82.
Golman K, Ardenkjær-Larsen JH, Petersson JS, Månsson S, Leunbach I. Molecular imaging with endogenous substances. Proc Natl Acad Sci U S A. 2003;100:10435–9.PubMedPubMedCentralCrossRef
83.
Golman K, Lerche M, Pehrson R, Ardenkjaer-Larsen JH. Metabolic imaging by hyperpolarized 13C magnetic resonance imaging for in vivo tumor diagnosis. Cancer Res. 2006;66:10855–60.PubMedCrossRef
84.
Kurhanewicz J, Vigneron DB, Brindle K, Chekmenev EY, Comment A, Cunningham CH, et al. Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. Neoplasia. 2011;13:81–97.PubMedPubMedCentralCrossRef
85.
Witney TH, Kettunen MI, Day SE, Hu D, Neves AA, Gallagher FA, et al. A comparison between radiolabeled fluorodeoxyglucose uptake and hyperpolarized 13C-labeled pyruvate utilization as methods for detecting tumor response to treatment. Neoplasia. 2009;11:574–82.PubMedPubMedCentralCrossRef
86.
Nelson SJ, Kurhanewicz J, Vigneron DB, Larson PE, Harzstark AL, Ferrone M, et al. Metabolic imaging of patients with prostate cancer using hyperpolarized [1-13C] pyruvate. Sci Transl Med. 2013;5:198ra108–8.
87.
Rodrigues TB, Serrao EM, Kennedy BW, Hu D-E, Kettunen MI, Brindle KM. Magnetic resonance imaging of tumor glycolysis using hyperpolarized 13C-labeled glucose. Nat Med. 2014;20:93–7.PubMedCrossRef
88.
Albers MJ, Bok R, Chen AP, Cunningham CH, Zierhut ML, Zhang VY, et al. Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res. 2008;68:8607–15.PubMedPubMedCentralCrossRef
89.
Gallagher FA, Kettunen MI, Hu D-E, Jensen PR, Karlsson M, Gisselsson A, et al. Production of hyperpolarized [1, 4-13C2] malate from [1, 4-13C2] fumarate is a marker of cell necrosis and treatment response in tumors. Proc Natl Acad Sci U S A. 2009;106:19801–6.PubMedPubMedCentralCrossRef
90.
Sarkar R, Comment A, Vasos PR, Jannin S, Gruetter R, Bodenhausen G, et al. Proton NMR of 15N-choline metabolites enhanced by dynamic nuclear polarization. J Am Chem Soc. 2009;131:16014–5.PubMedCrossRef
91.
Keshari KR, Wilson DM, Chen AP, Bok R, Larson PE, Hu S, et al. Hyperpolarized [2-13C]-fructose: a hemiketal DNP substrate for in vivo metabolic imaging. J Am Chem Soc. 2009;131:17591–6.PubMedPubMedCentralCrossRef
92.
Wehrl HF, Sauter AW, Divine MR, Pichler BJ. Combined PET/MR: a technology becomes mature. J Nucl Med. 2015;56:165–8.PubMedCrossRef
93.
Wehrl HF, Wiehr S, Divine MR, Gatidis S, Gullberg GT, Maier FC, et al. Preclinical and translational PET/MR imaging. J Nucl Med. 2014;55:11S–8S.PubMedCrossRef
94.
Judenhofer MS, Wehrl HF, Newport DF, Catana C, Siegel SB, Becker M, et al. Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med. 2008;14:459–65.PubMedCrossRef
95.
96.
Mueller-Klieser W, Walenta S, Paschen W, Kallinowski F, Vaupel P. Metabolic imaging in microregions of tumors and normal tissues with bioluminescence and photon counting. J Natl Cancer Inst. 1988;80:842–8.PubMedCrossRef
97.
Walenta S, Wetterling M, Lehrke M, Schwickert G, Sundfør K, Rofstad EK, et al. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res. 2000;60:916–21.PubMed
98.
Ziebart T, Walenta S, Kunkel M, Reichert TE, Wagner W, Mueller-Klieser W. Metabolic and proteomic differentials in head and neck squamous cell carcinomas and normal gingival tissue. J Cancer Res Clin Oncol. 2011;137:193–9.PubMedCrossRef
99.
Modica-Napolitano JS, Singh KK. Mitochondrial dysfunction in cancer. Mitochondrion. 2004;4:755–62.PubMedCrossRef
100.
López-Ríos F, Sánchez-Aragó M, García-García E, Ortega ÁD, Berrendero JR, Pozo-Rodríguez F, et al. Loss of the mitochondrial bioenergetic capacity underlies the glucose avidity of carcinomas. Cancer Res. 2007;67:9013–7.PubMedCrossRef
101.
Pedersen PL, Morris HP. Uncoupler-stimulated adenosine triphosphatase activity deficiency in intact mitochondria from Morris hepatomas and ascites tumor cells. J Biol Chem. 1974;249:3327–34.PubMed
102.
Jain M, Nilsson R, Sharma S, Madhusudhan N, Kitami T, Souza AL, et al. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science. 2012;336:1040–4.PubMedPubMedCentralCrossRef
103.
Emwas A-HM. The strengths and weaknesses of NMR spectroscopy and mass spectrometry with particular focus on metabolomics research. Metabonomics Methods Protoc. 2015:161-193.
104.
Fan T, Lane AN, Higashi RM, Farag MA, Gao H, Bousamra M, et al. Altered regulation of metabolic pathways in human lung cancer discerned by 13C stable isotope-resolved metabolomics (SIRM). Mol Cancer. 2009;8:1476–4598.
105.
106.
Chen Q, Wu J, Zhang Y, Lin J-M. Qualitative and quantitative analysis of tumor cell metabolism via stable isotope labeling assisted microfluidic chip electrospray ionization mass spectrometry. Anal Chem. 2012;84:1695–701.PubMedCrossRef
107.
Hirayama A, Kami K, Sugimoto M, Sugawara M, Toki N, Onozuka H, et al. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res. 2009;69:4918–25.PubMedCrossRef
108.
Chan ECY, Koh PK, Mal M, Cheah PY, Eu KW, Backshall A, et al. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J Proteome Res. 2008;8:352–61.CrossRef
109.
Li M, Song Y, Cho N, Chang JM, Koo HR, Yi A, et al. An HR-MAS MR metabolomics study on breast tissues obtained with core needle biopsy. PLoS One. 2011;6:e25563.PubMedPubMedCentralCrossRef
110.
Denkert C, Budczies J, Kind T, Weichert W, Tablack P, Sehouli J, et al. Mass spectrometry–based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res. 2006;66:10795–804.PubMedCrossRef
111.
Minn H, Joensuu H, Ahonen A, Klemi P. Florodeoxyglucose imaging: A method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. Cancer. 1988;61:1776–81.PubMedCrossRef
112.
Krylov SN, Zhang Z, Chan NW, Arriaga E, Palcic MM, Dovichi NJ. Correlating cell cycle with metabolism in single cells: combination of image and metabolic cytometry. Cytometry. 1999;37:14–20.PubMedCrossRef
113.
Quistorff B, Haselgrove JC, Chance B. High spatial resolution readout of 3-D metabolic organ structure: an automated, low-temperature redox ratio-scanning instrument. Anal Biochem. 1985;148:389–400.PubMedCrossRef
114.
Chance B, Schoener B, Oshino R, Itshak F, Nakase Y. Oxidation-reduction ratio studies of mitochondria in freeze-trapped samples. NADH and flavoprotein fluorescence signals. J Biol Chem. 1979;254:4764–71.PubMed
115.
Ramanujam N, Richards-Kortum R, Thomsen S, Mahadevan-Jansen A, Follen M, Chance B. Low temperature fluorescence imaging of freeze-trapped human cervical tissues. Opt Express. 2001;8:335–43.PubMedCrossRef
116.
117.
Li LZ, Zhou R, Xu HN, Moon L, Zhong T, Kim EJ, et al. Quantitative magnetic resonance and optical imaging biomarkers of melanoma metastatic potential. Proc Natl Acad Sci U S A. 2009;106:6608–13.PubMedPubMedCentralCrossRef
118.
Zhang Z, Li H, Liu Q, Zhou L, Zhang M, Luo Q, et al. Metabolic imaging of tumors using intrinsic and extrinsic fluorescent markers. Biosens Bioelectron. 2004;20:643–50.PubMedCrossRef
119.
Xu HN, Nioka S, Li LZ. Imaging heterogeneity in the mitochondrial redox state of premalignant pancreas in the pancreas-specific PTEN-null transgenic mouse model. Biomarker Res. 2013;1:207–13.CrossRef
120.
Xu HN, Zheng G, Tchou J, Nioka S, Li LZ. Characterizing the metabolic heterogeneity in human breast cancer xenografts by 3D high resolution fluorescence imaging. SpringerPlus. 2013;2:73.PubMedPubMedCentralCrossRef
121.
Xu HN, Nioka S, Glickson JD, Chance B, Li LZ. Quantitative mitochondrial redox imaging of breast cancer metastatic potential. J Biomed Opt. 2010, 15:036010-036010-036010.
122.
Xu HN, Feng M, Moon L, Dolloff N, El-Deiry W, Li LZ. Redox imaging of the p53-dependent mitochondrial redox state in colon cancer ex vivo. J Innov Opt Health Sci. 2013;6:1350016.PubMedPubMedCentralCrossRef
123.
124.
Walsh AJ, Cook RS, Sanders ME, Aurisicchio L, Ciliberto G, Arteaga CL, et al. Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer. Cancer Res. 2014;74:5184–94.PubMedPubMedCentralCrossRef
125.
Shah AT, Beckler MD, Walsh AJ, Jones WP, Pohlmann PR, Skala MC. Optical metabolic imaging of treatment response in human head and neck squamous cell carcinoma. PLoS One. 2014;9:e90746.PubMedPubMedCentralCrossRef
126.
Ramanujan VK, Zhang J-H, Biener E, Herman B. Multiphoton fluorescence lifetime contrast in deep tissue imaging: prospects in redox imaging and disease diagnosis. J Biomed Opt. 2005, 10:051407-051407-051411.
127.
Sung JH, Shuler ML. A micro cell culture analog (μCCA) with 3-D hydrogel culture of multiple cell lines to assess metabolism-dependent cytotoxicity of anti-cancer drugs. Lab Chip. 2009;9:1385–94.PubMedCrossRef
128.
Hu F, Chen Z, Zhang L, Shen Y, Wei L, Min W. Vibrational imaging of glucose uptake activity in live cells and tissues by stimulated raman scattering. Angew Chem. 2015;127:9959–63.CrossRef
129.
O’Neil RG, Wu L, Mullani N. Uptake of a fluorescent deoxyglucose analog (2-NBDG) in tumor cells. Mol Imaging Biol. 2005;7:388–92.PubMedCrossRef
130.
Louzao MC, Espiña B, Vieytes MR, Vega FV, Rubiolo JA, Baba O, et al. “Fluorescent glycogen” formation with sensibility for in vivo and in vitro detection. Glycoconj J. 2008;25:503–10.PubMedCrossRef
131.
Vu NT, Zeta T, Comin-Anduix B, Søndergaard JN, Silverman RW, Chang CY, et al. A β-camera integrated with a microfluidic chip for radioassays based on real-time imaging of glycolysis in small cell populations. J Nucl Med. 2011;52:815–21.PubMedPubMedCentralCrossRef
132.
Pratx G, Chen K, Sun C, Axente M, Sasportas L, Carpenter C, et al. High-resolution radioluminescence microscopy of 18F-FDG uptake by reconstructing the β-ionization track. J Nucl Med. 2013;54:1841–6.PubMedCrossRef
133.
Sengupta D, Miller S, Marton Z, Chin F, Nagarkar V, Pratx G. Bright Lu2O3: Eu Thin‐Film Scintillators for High‐Resolution Radioluminescence Microscopy. Adv Healthc Mater. 2015;4(14):2064–70.
Metadata
Title
Imaging metabolic heterogeneity in cancer
Authors
Debanti Sengupta
Guillem Pratx
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2016
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/s12943-015-0481-3

Other articles of this Issue 1/2016

Molecular Cancer 1/2016 Go to the issue

Research

Bit1 knockdown contributes to growth suppression as well as the decreases of migration and invasion abilities in esophageal squamous cell carcinoma via suppressing FAK-paxillin pathway

Research

Over-expression of cathepsin B in hepatocellular carcinomas predicts poor prognosis of HCC patients

Research

Effect of low doses of actinomycin D on neuroblastoma cell lines

Research

Cancer somatic mutations cluster in a subset of regulatory sites predicted from the ENCODE data

Review

Long noncoding RNAs as novel predictors of survival in human cancer: a systematic review and meta-analysis

Review

Detection of cancer cells using SapC-DOPS nanovesicles
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits